NEW YORK (GenomeWeb) – BioTheranostics announced today that it has raised $32 million in a private equity financing round, and will be spun off from parent company BioMérieux as a result.

The financing round was led by MVM Life Science Partners, with participation from Canepa Advanced Healthcare Fund and HealthQuest Capital. BioMérieux will remain a minority shareholder in the newly independent company.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more